Objectives: To analyze the serum and urine metabolites present in type 2 diabetes mellitus (T2DM) patients and T2DM patients with diabetic peripheral neuropathy (DPN) and to select differentially expressed biomarkers for early diagnosis of DPN.
Methods: Serum and urine metabolites from 74 T2DM patients with peripheral neuropathy and 41 without peripheral neuropathy were analyzed using gas chromatograph system with time-of-flight mass spectrometer metabolomics to detect biomarkers of peripheral neuropathy in T2DM.
Results: There were increased serum triglycerides, alanine aminotransferase, and decreased C-peptide, and total cholesterol levels in T2DM patients with DPN compared to those without peripheral neuropathy. Metabolomic analysis revealed visible differences in metabolic characteristics between two groups, and overall 53 serum differential metabolites and 56 urine differential metabolites were identified with variable influence on projection (VIP) >1 and <0.05. To further analyze the correlation between the identified metabolites and DPN, four serum metabolites and six urine metabolites were selected with VIP>2, and fold change (FC) >1, including serum β-alanine, caproic acid, β-alanine/L-aspartic acid, and L-arabinose/L-arabitol, and urine gluconic acid, erythritol, galactonic acid, guanidoacetic acid, cytidine, and aminoadipic acid. Furthermore, five serum biomarkers and six urine biomarkers were found to show significant changes (<0.05, VIP>1, and FC>1) respectively in patients with mild, moderate, and severe DPN. In addition, we found that glyoxylate and dicarboxylate metabolism was a differential metabolic pathway not only between T2DM and DPN, but also among different degrees of DPN. The differential metabolites such as β-alanine and caproic acid are expected to be biomarkers for DPN patients, and the significant changes in glyoxylate and dicarboxylate metabolism may be related to the pathogenesis of DPN.
Conclusion: There were serum and urine spectrum metabolomic differences in patients with DPN, which could serve as biomarkers for T2DM and DPN patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452362 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Novel antimicrobial strategies for diabetic foot infections: addressing challenges and resistance.
Acta Diabetol
January 2025
Department of Microbiology, Hind Institute of Medical Sciences, Mau, Ataria, Sitapur, Uttar Pradesh, India.
Aims: This review examines the challenges posed by Diabetic Foot Infections (DFIs), focusing on the impact of neuropathy, peripheral arterial disease, immunopathy, and the polymicrobial nature of these infections. The aim is to explore the factors contributing to antimicrobial resistance and assess the potential of novel antimicrobial treatments and drug delivery systems in improving patient outcomes.
Method: A comprehensive analysis of existing literature on DFIs was conducted, highlighting the multifactorial pathogenesis and polymicrobial composition of these infections.
Status of diabetes mellitus in different regions of KSA and update on its management.
Front Clin Diabetes Healthc
December 2024
Department of Basic Sciences, College of Medicine, Sulaiman Al Rajhi University, Al-Bukairyah, Saudi Arabia.
Background: Complications of diabetes and its associated comorbidities can cause rapid progression of type II diabetes mellitus (T2DM). It comes at high costs and affects a patient's quality of life. We aim to assess T2DM in KSA, including the demographics, medications, complications, and comorbidities, as it remains an integral part of Vision 2030.
View Article and Find Full Text PDFNeutrophil-Lymphocyte Ratio and Urine Albumin-Creatinine Ratio As Indicators of Microvascular Complications in Type 2 Diabetes Mellitus: A Cross-Sectional Study.
Cureus
December 2024
Internal Medicine, Kempegowda Institute of Medical Sciences, Bengaluru, IND.
Background Type 2 diabetes mellitus (T2DM) is associated with a high risk of developing microvascular complications such as diabetic nephropathy, diabetic neuropathy (DN), and diabetic retinopathy (DR), leading to significant morbidity. Early detection of these complications is crucial for improving patient outcomes. Neutrophil-lymphocyte ratio (NLR) and urine albumin-creatinine ratio (UACR) show promise as cost-effective and accessible biomarkers for the early detection of microvascular complications in T2DM.
View Article and Find Full Text PDFEnhancing diabetic rat peripheral nerve conduction velocity parameters through the potent effects of MitoTEMPO.
Heliyon
December 2024
Baskent University, Faculty of Medicine, Department of Biophysics, Ankara, Türkiye.
The efficacy of MitoTEMPO, a mitochondria-targeted antioxidant, in altering nerve fiber conduction properties within the sciatic nerve of streptozotocin (STZ)-induced diabetic rats, a model for diabetic neuropathy characterized by myelinated fiber atrophy and nodal abnormalities. Utilizing the STZ-induced diabetic rat model, we assessed the impact of MitoTEMPO on nerve function through compound action potential (CAP) analysis and histological evaluation. Key indicators such as maximum depolarization (MD), CAP area, and conduction velocity distribution (CVD) were measured to gauge MitoTEMPO's neuroprotective effects, alongside physical parameters like weight and blood glucose levels.
View Article and Find Full Text PDFDisrupting the transmembrane domain interface between PMP22 and MPZ causes peripheral neuropathy.
iScience
November 2024
Department of Molecular Physiology and Biophysics, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA.
Peripheral Myelin Protein 22 (PMP22) and MPZ are abundant myelin membrane proteins in Schwann cells. The MPZ adhesion protein holds myelin wraps together across the intraperiod line. PMP22 is a tetraspan protein belonging to the Claudin superfamily.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!